It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Bridge Study: Bridging Anticoagulation

Clinical Trial Title: 
Bridge: Bridging Anticoagulation for Patients with Atrial Fibrillation
Clinical Trial Protocol ID: 
10061504
Clinical Trial Investigator Name: 
Stuart W. Rosenbush, MD
Clinical Trial Protocol Description: 

The Bridge study will determine whether a bridging blood thinner called dalteparin is helpful or harmful for people with atrial fibrillation who stop taking warfarin in preparation for surgery or another procedure.

Clinical Trial Eligibility Criteria: 

You may be eligible for this study if you:

  • Are 18 years of age or older
  • Have chronic atrial fibrillation
  • Have been treated with Coumadin for at least three months

This is a partial list of eligibility and exclusion criteria. To inquire whether you are eligible for this study, please call the contact number provided. If you choose to inquire via email, please refer to the study title in your correspondence.

Clinical Trial Area: 
Heart and Vascular Conditions
Contact Phone: 
(312) 942-8144
Contact Name: 
Sherry Nelson